Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

Federle, Michael P.; Chezmar, J L; Rubin, Daniel L.; Weinreb, Jeffrey C.; Freeny, Patrick C.; Schmiedl, Udo P.; Brown, Jeffrey J.; Borrello, Joseph A.; Lee, Joseph K. T.; Semelka, Richard C.; Mattrey, Robert F.; Dachman, Abraham H.; Saini, Sanjay; Harms, Steven E.; Mitchell, Donald G.; Anderson, Mark; Halford, Hollis H.; Bennett, William F.; Young, Stuart W.; Rifkin, Matthew D.; Gay, Spencer B.; Ballerini, Rocco; Sherwin, Paul; Robison, Ronald O.

doi:10.1002/1522-2586(200011)12:5<689::aid-jmri5>3.0.co;2-z

Cited by 68 publications

(39 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following intravenous administration, Mn is taken up by the hepatocytes. This leads, as a consequence of T1-shortening, to an increased signal intensity of normal hepatic parenchyma, thus enhancing contrast between liver and focal lesions Several studies have investigated the usefulness of MRI after administration of MnDPDP [13,14,15,16,17,18,19]. There appears to be consensus that MnDPDP-enhanced MRI improves lesion conspicuity and increases lesion detection rate.…”

Section: Resultsmentioning

confidence: 99%

Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT

et al. 2004

View full text Add to dashboard Cite

The aim of this study was to compare unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT in the detection of hepatic colorectal metastases. Forty-four patients with hepatic colorectal metastases were examined with unenhanced and MnDPDP-enhanced MRI and with unenhanced and contrast-enhanced spiral CT. The MR examination protocol included baseline T1-weighted spin-echo (SE), T1-weighted gradient-recalled-echo (GRE), and T2-weighted fast-SE sequences; and T1-weighted SE and T1-weighted GRE sequences obtained 30-60 min after administration of 0.5 micromol/kg (0.5 ml/kg) mangafodipir trisodium (MnDPDP). Images were interpreted by three blinded readers. Findings at CT and MRI were compared with those at intraoperative US, which were used as term of reference. Intraoperative US detected 128 metastases. In a lesion-by-lesion analysis, the overall detection rate was 71% (91 of 128) for spiral CT, 72% (92 of 128) for unenhanced MRI, and 90% (115 of 128) for MnDPDP-enhanced MRI. MnDPDP-enhanced MRI was more sensitive than either unenhanced MRI ( p<0.0001) or spiral CT ( p=0.0007). In a patient-by-patient analysis, agreement with gold standard was higher for MnDPDP-enhanced MRI (33 of 44 cases) than for spiral CT (22 of 44 cases, p=0.0023) and unenhanced MRI (21 of 44 cases, p=0.0013). MnDPDP-enhanced MRI is superior to unenhanced MRI and spiral CT in the detection of hepatic colorectal metastases.

show abstract

Section: Resultsmentioning

confidence: 99%

Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT

et al. 2004

View full text Add to dashboard Cite

show abstract

“…c Corresponding axial MSCT image (150 ml of contrast agent, portal venous phase, 3 mm slice thickness) shows only two metastases (arrows). The third lesion was also not depicted on adjacent slices trials, mangafodipir-enhanced MRI was comparable or superior to CT [44]. However, in both studies, helical CT was not used for all patients.…”

Section: Lesion Detectionmentioning

confidence: 90%

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

2004

View full text Add to dashboard Cite

Hepatobiliary contrast agents with uptake into hepatocytes followed by variable biliary excretion represent a unique class of cell-specific MR contrast agents. Two hepatobiliary contrast agents, mangafodipir trisodium and gadobenate dimeglumine, are already clinically approved. A third hepatobiliary contrast agent, Gd-EOB-DTPA, is under consideration. The purpose of this review is to provide an overview on the properties, clinical development and application of these three hepatobiliary contrast agents. Bolus injectable paramagnetic hepatobiliary contrast agents combine established features of extracellular agents with the advantages of hepatocyte specificity. The detection and characterisation of focal liver disease appears to be improved compared to unenhanced MRI, MRI with unspecific contrast agents and contrast-enhanced CT. To decrease the total time spent by a patient in the MR scanner, it is advisable to administer the agent immediately after acquisition of unenhanced T1-w MRI. After infusion or bolus injection (with dynamic FS-T1-w 2D or 3D GRE) of the contrast agent, moderately and heavily T2w images are acquired. Post-contrast T1-w MRI is started upon completion of T2-w MRI for mangafodipir trisodium and Gd-EOB-DTPA as early as 20 min following injection, while gadobenate dimeglumine scans are obtained >60 min following injection. Post-contrast acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by MSCT combined with an unparalleled improvement in tumour-liver contrast. The individual decision that hepatobiliary contrast agent one uses is partly based on personal preferences. No comparative studies have been conducted comparing the advantages or disadvantages of all three agents directly against each other.

show abstract

“…However, the goal to measure tissue function was pursued by making chelates of Mn 2+ . Manganese dipyridoxaldiphosphate (MnDPDP) is presently FDA approved for liver imaging for negative enhancement of tumors in the liver [33]. In addition, there has been much work demonstrating the usefulness of MnDPDP for imaging cardiac ischemia [10,11,28,34].…”

Section: Systemic Administration Of Manganese Leads To Useful Mri Conmentioning

confidence: 99%

Manganese Enhanced Magnetic Resonance Imaging

Lee¹,

Koretsky²

2004

CPB

View full text Add to dashboard Cite

Abstract:Manganese is an essential metal that participates as a co-factor in a number of critical biological functions such as electron transport, detoxification of free radicals, and synthesis of neurotransmitters. Like other heavy metals, high concentrations of manganese are toxic. For example, chronic overexposure to manganese leads to movement disorders. In order to maintain this balance between being an essential participant in enzyme function and being a toxic heavy metal, a rich biology has evolved to transport and store manganese. Paramagnetic forms of manganese ions are potent MRI relaxation agents. Indeed, Mn 2+ was the first contrast agent proposed for use in MRI. Recently, there is renewed interest in combining the strong MRI relaxation effects of Mn 2+ with its unique biology in order to expand the range of information that can be measured by MRI. Manganese Enhanced MRI is being developed to give unique tissue contrast, assess tissue viability, act as a surrogate marker of calcium influx into cells and trace neuronal connections. In this article we review recent work and point out prospects for the future uses of manganese enhanced MRI.

show abstract

Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

Cited by 68 publications

References 60 publications

Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT

Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

Manganese Enhanced Magnetic Resonance Imaging

Contact Info

Product

Resources

About